Identification of HOXA9 methylation as an epigenetic biomarker predicting prognosis and guiding treatment choice in acute myeloid leukemia
HOXA9 methylation linked to HOXA9 expression correlates with diverse genetic abnormalities of AML, such as normal karyotype, t(15;17), t(8;21), t(16;16) and FLT3, NPM1 and DNMT3A mutations. Moreover, HOXA9 hypomethylation may be associated with adverse prognosis, and may guide treatment choice in AML.
Authors
- Liang Qiao (ORCID: https://orcid.org/0000-0002-4940-2727)
- Ting‐juan Zhang (ORCID: https://orcid.org/0000-0003-1533-0646)
- Jing‐dong Zhou (ORCID: https://orcid.org/0000-0003-1476-926X)
- Jun Qian (ORCID: https://orcid.org/0000-0001-7697-2875)
- Zi‐jun Xu (ORCID: https://orcid.org/0000-0002-5051-6799)
- Yangjing Zhao (ORCID: https://orcid.org/0000-0002-6706-782X)
- Xinlong Zhang (ORCID: https://orcid.org/0009-0004-8040-0553)
- Yun Wang (ORCID: https://orcid.org/0000-0002-5836-0872)
- Fei Xie (ORCID: https://orcid.org/0000-0002-3636-2682)
Institutions
- Jiangsu University (CN)
- Nantong University (CN)
- Affiliated Hospital of Nantong University (CN)
- Affiliated Hospital of Jiangsu University (CN)
- Zhanjiang Experimental Station (CN)
- Shanghai Clinical Research Center (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-02-07
- DOI
- https://doi.org/10.1186/s12885-025-13633-y
- Citations
- 6
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 10.62
Funders
- Jiangsu Commission of Health
- National Natural Science Foundation of China
- Government of Jiangsu Province
- Natural Science Foundation of Jiangsu Province